On April 7, 2026, Abeona Therapeutics Inc. (Nasdaq: ABEO) revealed the addition of Keith A. Goldan as an independent member to its Board of Directors, starting from April 1, 2026. Mr. Goldan will also undertake the role of Chairman of Abeona’s Audit Committee. With over 20 years of financial expertise in publicly traded commercial-stage biotechnology and specialty pharmaceutical firms, Mr. Goldan's appointment underscores Abeona’s commitment to enhancing its leadership squad to drive forward strategic and financial goals.